Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests

07 October 2020 BioCentury News
Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.

Related Services


IMMEX Highlights –REMINDER of deadline for filing the Annual Operations Report
20 April 2021
Dashboard Insights
Foley Weekly Automotive Report
20 April 2021
Dashboard Insights
Podcast Episode 44: Mike Lappin, Of Counsel
20 April 2021
Foley Career Perspectives
There’s a New Sheriff in Town – OSHA Is Getting Serious About COVID-19 Fines
19 April 2021
Labor & Employment Law Perspectives
2021 AANP National Conference
15 June - 31 August 2021
Virtual Conference
HCCA Orange County Regional Healthcare Compliance Conference
11 June 2021
Virtual Conference
Rx Pricing and Reimbursement Summit
24-25 May 2021
Virtual Conference
The Comeback: Sports in a Worldwide Pandemic (Series)
12 May 2021